6.9750% until 3/1/2029 (USXA)

.028 cleared ~Rig

So here's my question to you. When they dilute what happens to the share price? Does it go up or down? Sandbox would not have needed to dilute.

$CNEY china name know for big moves, been steady here think itll get found soon

$CNEY china name know for big moves, been steady here think itll get found soon

Maybe. But what matters more: preserving a journal publication, or getting MAA approval?

NWBO already has a JAMA paper. Does it need another journal article, or does it need MAA approval?

If the PSM/IPD analysis is important to approval, MHRA does not need to wait for a

MMs are surely trying to walk this down every time it hits around .11. They want in kept in their channel, whoever it is.

Tutes were buying Ernie . Gupta doesn't control the India based FDA inspectors .
Only thing he can do is raise some cash thru the ATM before June 29th , in case you know what hits the fan ...which he did .
JMO
Kiwi

Sure.

It will be no bid Wed, next Wed etc etc

I often think back to the disconnect we had here when thinking about V in Europe. Most of us could not understand how analysts were modeling very little for the EU. In retrospect, they obviously knew better than most of us. No question a Euro-centric pharma would have been better at launching V i

PNC Raises Common Stock Dividend to $2.00 Per ShareJuly 6, 2026 11:32 AM
PR Newswire (US) class="legendSpanClass"PITTSBURGH, class="legendSpanClass"July 6, 2026 /PRNewswire/ -- The board of directors of The PNC Financial Services Group,

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMADJuly 6, 2026 11:40 AM
PR Newswire (Canada) Issued on behalf of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), formerly LIXTE

#1.1 SPX Cycles Daily Update. 60-S-2 (Overdue) confirmed during the 1ST hour. Next Possibilities: 60-2 (Extreme Overdue) 7530.79, 60-E-2 7623.60, 60-S-1 (Overdue) 7474.44, 60-1 7434.37. Possibility of D-2 (Extreme Overdue) today at the close, projected high 7560.87, high due today. Possibility o

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMADJuly 6, 2026 11:40 AM
PR Newswire (Canada) Issued on behalf of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), formerly LIXTE

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMADJuly 6, 2026 11:40 AM
PR Newswire (Canada) Issued on behalf of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), formerly LIXTE

HyGro,
“Journal's are not a regulator data source”
Fact ✅: Journals are a source that regulators consider all the time. Independently peer-reviewed medical literature is highly relevant & undeniably significant…

Regulatory agencies such as FDA & MHRA can & do conside

It’s always been strange to me how certain people can buy and sell at those numbers. Definitely seems wrong. Everyone should be in the same boat only getting to work with trips

In any case NWBO's achieving any real value depends on proof of commercial viability. I.e. MHRA approval. With that, the shares can seek a higher level. How high probably depends on seeing follow-on deal(s) and financing. Without it, NWBO is a merely research project and a failed attempt at commerci

$AABB Shareholder Update - Digital Asset & rGO Progress Report
https://www.youtube.com/watch?v=Rk4IC8tPrSI

https://www.youtube.com/watch?v=Rk4IC8tPrSI

$AABB Shareholder Update - Digital Asset & rGO Progress Report
https://www.youtube.com/watch?v=Rk4IC8tPrSI

https://www.youtube.com/watch?v=Rk4IC8tPrSI

investors allowed LP to hand pick her board which provides all the protection she needs. investors need to take the first step this year and stop reapproving them to the board including LP herself who needs our vote to reappoint.

#1.1 SPX Cycles Daily Update. 60-S-2 (Overdue) confirmed during the 1ST hour. Next Possibilities: 60-2 (Extreme Overdue) 7530.79, 60-E-2 7623.60, 60-S-1 (Overdue) 7474.44, 60-1 7434.37. Possibility of D-2 (Extreme Overdue) today at the close, projected high 7560.87, high due today. Possibility o

Good buying op. Story remains the same . OLC will likely be the best in class pho lowering med for dialysis patients .
Its just a question of timing .
Do the India based FDA inspectors get the inspection done in the next week or two and then the FDA issues a Class 1 resubmission ...o

Do whatever makes you happy. I’m fine with real science. I’ll keep getting COVID boosters and every other recommended vaccine. As for AVXL, the stock is down and no news. I was hoping for a PR on the Monday after the 4th of July weekend. Hopes and dreams.